CN108430471B - 因子XIa抑制剂 - Google Patents
因子XIa抑制剂 Download PDFInfo
- Publication number
- CN108430471B CN108430471B CN201680059577.7A CN201680059577A CN108430471B CN 108430471 B CN108430471 B CN 108430471B CN 201680059577 A CN201680059577 A CN 201680059577A CN 108430471 B CN108430471 B CN 108430471B
- Authority
- CN
- China
- Prior art keywords
- mmol
- alkyl
- mixture
- stirred
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248075P | 2015-10-29 | 2015-10-29 | |
| US62/248075 | 2015-10-29 | ||
| PCT/US2016/058362 WO2017074832A1 (en) | 2015-10-29 | 2016-10-24 | FACTOR XIa INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108430471A CN108430471A (zh) | 2018-08-21 |
| CN108430471B true CN108430471B (zh) | 2021-07-09 |
Family
ID=58631804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680059577.7A Active CN108430471B (zh) | 2015-10-29 | 2016-10-24 | 因子XIa抑制剂 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10214512B2 (enExample) |
| EP (1) | EP3368036B1 (enExample) |
| JP (1) | JP6892858B2 (enExample) |
| KR (1) | KR102727485B1 (enExample) |
| CN (1) | CN108430471B (enExample) |
| AU (1) | AU2016344476B2 (enExample) |
| BR (1) | BR112018008506B8 (enExample) |
| CA (1) | CA2998902C (enExample) |
| MA (1) | MA43128A (enExample) |
| MX (1) | MX387515B (enExample) |
| RU (1) | RU2728783C2 (enExample) |
| WO (1) | WO2017074832A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020086416A1 (en) * | 2018-10-25 | 2020-04-30 | Merck Sharp & Dohme Corp. | FACTOR Xla INHIBITORS |
| WO2020102098A1 (en) * | 2018-11-13 | 2020-05-22 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| CN113677682B (zh) | 2019-04-16 | 2023-05-30 | 华润生物医药有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| WO2021013209A1 (zh) * | 2019-07-23 | 2021-01-28 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| AU2021306250A1 (en) * | 2020-07-10 | 2023-02-16 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
| WO2022164735A1 (en) * | 2021-01-28 | 2022-08-04 | Merck Sharp & Dohme Llc | Factor xia inhibitors |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7262210B2 (en) * | 2005-04-20 | 2007-08-28 | Janssen Pharmaceutica N.V. | Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls |
| US7829584B2 (en) * | 2006-03-21 | 2010-11-09 | Janssen Pharmaceutica Nv | Pyridines and pyridine N-oxides as modulators of thrombin |
| WO2014022767A1 (en) * | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0303901A2 (hu) | 2000-11-07 | 2004-03-01 | Bristol-Myers Squibb Co. | Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| EP1332131A2 (en) | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| WO2002060894A2 (en) | 2001-01-30 | 2002-08-08 | Bristol-Myers Squibb Company | Sulfonamide lactam inhibitors of factor xa |
| US6825208B2 (en) | 2001-08-20 | 2004-11-30 | Bristol-Myers Squibb Pharma Company | Tetrahydroquinoline derivatives as antithrombotic agents |
| AU2003243657A1 (en) | 2002-06-26 | 2004-01-19 | Bristol-Myers Squibb Company | Amino-bicyclic pyrazinones and pyridinones |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US20060074103A1 (en) | 2004-10-06 | 2006-04-06 | Corte James R | Cyclic beta-amino acid derivatives as factor Xa inhibitors |
| DE602005009252D1 (de) | 2004-12-08 | 2008-10-02 | Bristol Myers Squibb Co | Heterocyclische verbindungen als inhibitoren von faktor viia |
| ATE479676T1 (de) | 2005-01-10 | 2010-09-15 | Bristol Myers Squibb Co | Als antikoagulanzien verwendbare phenylglycinamid-derivate |
| CN101137412B (zh) | 2005-01-13 | 2012-11-07 | 布里斯托尔-迈尔斯·斯奎布公司 | 用作凝血因子XIa抑制剂的取代的二芳基化合物 |
| US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
| WO2007070826A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2007070816A2 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Thiophene derivatives as factor xia inhibitors |
| WO2008076805A2 (en) | 2006-12-15 | 2008-06-26 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| JP5318094B2 (ja) * | 2007-06-13 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | 凝固因子阻害剤としてのジペプチド類似体 |
| CN102026996B (zh) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
| US8828983B2 (en) | 2010-02-11 | 2014-09-09 | Bristol-Myers Squibb Company | Macrocycles as factor XIa inhibitors |
| TW201319068A (zh) * | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| JP6033318B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| IN2014CN02806A (enExample) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| PL2766346T3 (pl) | 2011-10-14 | 2017-09-29 | Bristol-Myers Squibb Company | Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA |
| DK2794597T3 (en) | 2011-12-21 | 2018-01-15 | Ono Pharmaceutical Co | PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS |
| JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| CA2880898A1 (en) * | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
| WO2014160592A2 (en) | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| ES2687498T3 (es) * | 2014-01-31 | 2018-10-25 | Bristol-Myers Squibb Company | Macrociclos con grupos P2¿ heterocíclicos como inhibidores del factor XIa |
| NO2760821T3 (enExample) * | 2014-01-31 | 2018-03-10 | ||
| WO2015123090A1 (en) * | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| US20150291606A1 (en) * | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrrolopyrimidine compounds |
| US9453018B2 (en) * | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| US20180162821A1 (en) * | 2016-12-14 | 2018-06-14 | Bristol-Myers Squibb Company | Factor xia macrocycles with novel p1 groups |
-
2016
- 2016-10-24 CA CA2998902A patent/CA2998902C/en active Active
- 2016-10-24 RU RU2018119015A patent/RU2728783C2/ru active
- 2016-10-24 WO PCT/US2016/058362 patent/WO2017074832A1/en not_active Ceased
- 2016-10-24 BR BR112018008506A patent/BR112018008506B8/pt active IP Right Grant
- 2016-10-24 JP JP2018521211A patent/JP6892858B2/ja active Active
- 2016-10-24 EP EP16860556.6A patent/EP3368036B1/en active Active
- 2016-10-24 US US15/771,538 patent/US10214512B2/en active Active
- 2016-10-24 CN CN201680059577.7A patent/CN108430471B/zh active Active
- 2016-10-24 MA MA043128A patent/MA43128A/fr unknown
- 2016-10-24 KR KR1020187013433A patent/KR102727485B1/ko active Active
- 2016-10-24 AU AU2016344476A patent/AU2016344476B2/en active Active
- 2016-10-24 MX MX2018005045A patent/MX387515B/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7262210B2 (en) * | 2005-04-20 | 2007-08-28 | Janssen Pharmaceutica N.V. | Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls |
| US7829584B2 (en) * | 2006-03-21 | 2010-11-09 | Janssen Pharmaceutica Nv | Pyridines and pyridine N-oxides as modulators of thrombin |
| WO2014022767A1 (en) * | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016344476B2 (en) | 2020-08-13 |
| MX2018005045A (es) | 2018-08-01 |
| EP3368036A4 (en) | 2019-04-17 |
| BR112018008506B1 (pt) | 2023-11-14 |
| EP3368036B1 (en) | 2022-07-20 |
| US10214512B2 (en) | 2019-02-26 |
| BR112018008506A2 (pt) | 2018-10-23 |
| KR20180073602A (ko) | 2018-07-02 |
| MX387515B (es) | 2025-03-18 |
| RU2018119015A (ru) | 2019-11-29 |
| AU2016344476A1 (en) | 2018-03-08 |
| US20180339977A1 (en) | 2018-11-29 |
| CN108430471A (zh) | 2018-08-21 |
| CA2998902A1 (en) | 2017-05-04 |
| JP2018531954A (ja) | 2018-11-01 |
| RU2728783C2 (ru) | 2020-07-31 |
| BR112018008506B8 (pt) | 2023-12-05 |
| EP3368036A1 (en) | 2018-09-05 |
| WO2017074832A1 (en) | 2017-05-04 |
| CA2998902C (en) | 2024-03-26 |
| RU2018119015A3 (enExample) | 2020-02-18 |
| JP6892858B2 (ja) | 2021-06-23 |
| MA43128A (fr) | 2018-09-05 |
| KR102727485B1 (ko) | 2024-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108430471B (zh) | 因子XIa抑制剂 | |
| EP3180327B1 (en) | FACTOR XIa INHIBITORS | |
| EP3148542B1 (en) | Factor xia inhibitors | |
| EP3283464B1 (en) | Factor xia inhibitors | |
| EP3180317B1 (en) | FACTOR XIa INHIBITORS | |
| EP3383847B1 (en) | FACTOR XIa INHIBITORS | |
| WO2016018702A1 (en) | FACTOR XIa INHIBITORS | |
| JP7776453B2 (ja) | 血漿カリクレイン阻害剤 | |
| CN107106548A (zh) | 因子XIa抑制剂 | |
| EP3258929B1 (en) | Factor ixa inhibitors | |
| EP4210694A1 (en) | Plasma kallikrein inhibitors | |
| EP2934536A1 (en) | FACTOR IXa INHIBITORS | |
| EP4149917B1 (en) | Factor xi activation inhibitors | |
| EP3976027B1 (en) | Quinoline derivatives as factor xi activation inhibitors | |
| CN116157154A (zh) | 血浆激肽释放酶抑制剂 | |
| RU2844952C1 (ru) | Ингибиторы калликреина плазмы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220906 Address after: new jersey Patentee after: MERCK SHARP & DOHME B.V. Address before: new jersey Patentee before: MERCK SHARP & DOHME Corp. |